文献速递神经核医学肿瘤 PET/CT

全集成PET/MRI实现脑葡萄糖代谢无创临床定量

Promise of Fully Integrated PET/MRI: Noninvasive Clinical Quantification of Cerebral Glucose Metabolism.
PubMed 文献 · J Nucl Med · 2019-08-02

该研究纳入10名健康志愿者,进行18F-FDG PET/MRI重测,开发全自动流程以无创绝对定量脑葡萄糖代谢率(CMRGlc)。基于T1加权MRI的伪CT衰减校正提取IDIF,与动脉血AIF参考标准比较,曲线下面积绝对百分比差异分别为1.4%±1.0%(CT-IDIF)和3.4%±2.6%(pCT-IDIF),区域CMRGlc差异小于6%。

要点

  • 全自动流程利用PET/MRI解剖代谢信息实现无创CMRGlc定量。
  • 基于MRI衰减校正的IDIF与AIF参考标准区域CMRGlc差异小于6%。
  • 方法有望推动全定量成像进入临床并提升诊断效能。

核心结论

  • 利用全集成PET/MRI的能力,开发了全自动计算流程,可在临床环境中无创测定区域CMRGlc值。

研究设计与样本

  • 10名健康志愿者(5男5女;27±7岁;70±10 kg)接受18F-FDG PET/MRI脑部重测检查。
  • 成像方案包括60分钟PET列表模式采集及同步MRI采集(三维TOF MR血管成像、MRI导航序列、T1加权MRI)。
  • 基于T1加权MRI的伪CT进行衰减校正,并以低剂量CT和动脉血采样(AIF)作为验证参考。

主要发现

  • CT-IDIF与pCT-IDIF的曲线下面积绝对百分比差异分别为1.4%±1.0%和3.4%±2.6%。
  • 基于CT-IDIF和pCT-IDIF的区域CMRGlc值与AIF参考值的绝对百分比差异小于6%。

关键数值与推荐

  • 流程包括基于MRI导航序列的运动校正和一种考虑背景异质性的新型部分容积校正。
  • CMRGlc图用于生成正常数据库,以辅助未来患者扫描中代谢异常的检测。

临床怎么用

  • 该全自动流程可在临床环境中实现无创区域CMRGlc定量,可能促进全定量成像在临床的推广。

局限性

  • 研究仅纳入10名健康志愿者,未在患者人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We describe a fully automated processing pipeline to support the noninvasive absolute quantification of the cerebral metabolic rate for glucose (CMRGlc) in a clinical setting. This pipeline takes advantage of "anatometabolic" information associated with fully integrated PET/MRI. Methods: Ten healthy volunteers (5 men and /5 women; 27 ± 7 y old; 70 ± 10 kg) underwent a test-retest 18F-FDG PET/MRI examination of the brain. The imaging protocol consisted of a 60-min PET list-mode acquisition with parallel MRI acquisitions, including 3-dimensional time-of-flight MR angiography, MRI navigators, and a T1-weighted MRI scan. State-of-the-art MRI-based attenuation correction was derived from T1-weighted MRI (pseudo-CT [pCT]). For validation purposes, a low-dose CT scan was also performed. Arterial blood samples were collected as the reference standard (arterial input function [AIF]). The developed pipeline allows the derivation of an image-derived input function (IDIF), which is subsequently used to create CMRGlc maps by means of a Patlak analysis. The pipeline also includes motion correction using the MRI navigator sequence as well as a novel partial-volume correction that accounts for background heterogeneity. Finally, CMRGlc maps are used to generate a normative database to facilitate the detection of metabolic abnormalities in future patient scans. To assess the performance of the developed pipeline, IDIFs extracted by both CT-based attenuation correction (CT-IDIF) and MRI-based attenuation correction (pCT-IDIF) were compared with the reference standard (AIF) using the absolute percentage difference between the areas under the curves as well as the absolute percentage difference in regional CMRGlc values. Results: The absolute percentage differences between the areas under the curves for CT-IDIF and pCT-IDIF were determined to be 1.4% ± 1.0% and 3.4% ± 2.6%, respectively. The absolute percentage difference in regional CMRGlc values based on CT-IDIF and pCT-IDIF differed by less than 6% from the reference values obtained from the AIF. Conclusion: By taking advantage of the capabilities of fully integrated PET/MRI, we developed a fully automated computational pipeline that allows the noninvasive determination of regional CMRGlc values in a clinical setting. This methodology might facilitate the proliferation of fully quantitative imaging into the clinical arena and, as a result, might contribute to improved diagnostic efficacy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Shiyam Sundar LK, Muzik O, Rischka L, et al. Promise of Fully Integrated PET/MRI: Noninvasive Clinical Quantification of Cerebral Glucose Metabolism. J Nucl Med. 2019. PMID: 31375567. doi:10.2967/jnumed.119.229567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。